Jubilant Biosys Limited (JBL); a Company registered under the Indian Companies Act, 1956 is a part of the Jubilant Life Sciences family of companies (a $1,293MM Sales Corporation) with R&D centers in India and business offices in Asia and North America. With our global reach, Jubilant Biosys provides comprehensive drug discovery services and contract research services – from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared) – in partnership with various pharmaceutical biotechnology, agrochemical and fine chemical companies.

Earlier Jubilant Biosys Limited (JBL) & Jubilant Chemsys Limited (JCL) operated as two separate legal entities. Starting 28th July 2020, Jubilant Chemsys limited is merged with Jubilant Biosys Limited as one legal company and continue to offer following services;
• Target Identification/ Target Validation to Lead Optimization/ Preclinical candidate, for multiple therapeutic areas viz; Oncology, Metabolic Disorders, CNS, Pain, Inflammation, Fibrosis and Respiratory diseases.
• Functional services comprising of computational chemistry/ molecular modeling, medicinal chemistry, synthetic chemistry, scale-up (Non-GMP & GMP), structural biology, ADME-PK, in-vitro and in-vivo biology and IND enabling GLP toxicology.
• Jubilant’ s CDMO offering include development and scale-up both non-GMP as well as GMP from kilo to ton scale in reactors sizes ranging from 0.1KL to 10KL.